Yoshitomi Pharmaceutical

Yoshitomi Pharmaceutical was a prominent Japanese pharmaceutical company specializing in the development and manufacture of neuropsychiatric and cardiovascular medications. Founded in 1940 as a joint venture, the company became a leader in the Japanese psychotropic drug market, notably introducing chlorpromazine to Japan and developing the widely used benzodiazepine analog etizolam. Through a series of strategic mergers beginning in 1998, the company's operations were integrated into what is now Mitsubishi Tanabe Pharma Corporation. Its legacy remains significant in the field of central nervous system therapeutics, with many of its original products continuing to be mainstay treatments in clinical practice. The company was historically headquartered in Osaka and maintained a strong focus on chemical synthesis and small molecule drug development.